Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Jill S. Clancy"'
Autor:
Joseph Chen, Gerson Peltz, Ana Ruiz-Garcia, Jennifer E. Hibma, Jill S. Clancy, Holger Thurm, Leonard P. James
Publikováno v:
Clinical pharmacology and therapeutics. 110(5)
Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). In the phase I/II s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::362ddfb16a7fc509881c380dc505a397
https://pubmed.ncbi.nlm.nih.gov/35394660
https://pubmed.ncbi.nlm.nih.gov/35394660
Autor:
Takashi Seto, Alice T. Shaw, Shirish M. Gadgeel, Benjamin Besse, Chia-Chi Lin, Sai-Hong Ignatius Ou, Jill S. Clancy, Joseph Chen, Gregory J. Riely, Eng Huat Tan, Holger Thurm, Todd M. Bauer, Gerson Peltz, D. Ross Camidge, Leonard P. James, Rita Chiari, Alessandra Bearz, Benjamin Solomon, Enriqueta Felip, Ross A. Soo, Antonello Abbattista, Jean-Francois Martini
Publikováno v:
The Lancet Oncology. 19:1654-1667
Summary Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30124db84ef40bde8436e51228a5807a
https://doi.org/10.1016/s1470-2045(18)30649-1
https://doi.org/10.1016/s1470-2045(18)30649-1
Autor:
Justin F. Gainor, Alice T. Shaw, Jill S. Clancy, Melissa Lynne Johnson, Sophie Postel-Vinay, Benjamin Solomon, Enriqueta Felip, Leonard P. James, Joseph Chen, Benjamin Besse, Alejandro Navarro, Todd M. Bauer, Jorg Dietrich, Antonello Abbattista, Jean-Francois Martini
Publikováno v:
The Lancet. Oncology
Summary Background Most patients with anaplastic lymphoma kinase ( ALK )-rearranged or ROS proto-oncogene 1 ( ROS1 )-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d310de90512d3b2487834f4a2e8462
http://europepmc.org/articles/PMC5777233
http://europepmc.org/articles/PMC5777233
Autor:
Elizabeth T. Masters, Benjamin Besse, Antonello Abbattista, Alice T. Shaw, D. Ross Camidge, Shirish M. Gadgeel, Gerson Peltz, Holger Thurm, Takashi Seto, Benjamin Solomon, Enriqueta Felip, Chia-Chi Lin, Solange Peters, Jill S. Clancy, Arlene Reisman, Ross A. Soo, Steven Kao, Alessandra Bearz
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 144
Objectives To evaluate patient-reported outcomes (PROs) from a phase 1/2 study (NCT01970865) in patients with anaplastic lymphoma kinase (ALK)- or ROS1-positive advanced non-small cell lung cancer (NSCLC) treated with lorlatinib 100 mg once daily. Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93480125ed4481968f36926a81bf0f8d
https://pubmed.ncbi.nlm.nih.gov/32344248
https://pubmed.ncbi.nlm.nih.gov/32344248
Autor:
D. Ross Camidge, Shirish M. Gadgeel, Miyako Satouchi, Rita Chiari, Benjamin Solomon, Enriqueta Felip, Holger Thurm, Benjamin Besse, Gregory J. Riely, Todd M. Bauer, Alice T. Shaw, Antonello Abbattista, Jean-Francois Martini, Jill S. Clancy, Sherry Li, Steven Kao, Chia-Chi Lin, Sai-Hong Ignatius Ou, Ross A. Soo
Publikováno v:
J Clin Oncol
PURPOSE Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non–small-cell lung cancer, including in patients who hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e9678efe6b065896f5445180096e95
https://europepmc.org/articles/PMC6544460/
https://europepmc.org/articles/PMC6544460/
Autor:
Heidi Mocikova, Agnieszka Giza, Mariajose Lechuga, Alessandra Romano, Joseph Boni, Sundra Ramanathan, Jill S. Clancy, Georg Hess, Pratyush Giri, Wojciech Jurczak, Michelle Casey
Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8815e6543b0760354707c48c66a8184
https://ruj.uj.edu.pl/xmlui/handle/item/93991
https://ruj.uj.edu.pl/xmlui/handle/item/93991
Autor:
Alice T. Shaw, C. Tanski, Jill S. Clancy, Ben Solomon, E. Felip, H. Mamdani, Rita Chiari, Joseph Chen, M. O'Gorman, D. Kim, Yazdi K. Pithavala, Jessica Bauman, S-H.I. Ou, Ross A. Soo, Alessandra Bearz, K. Lee
Publikováno v:
Journal of Thoracic Oncology. 14:S392-S393
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f89bc6cb919d1e761a34b4f66bfa5f4b
https://doi.org/10.1016/j.jtho.2019.08.799
https://doi.org/10.1016/j.jtho.2019.08.799
Autor:
Rita Chiari, Jill S. Clancy, Ben Solomon, Holger Thurm, Alice T. Shaw, S-H.I. Ou, Antonello Abbattista, G. J. Riely, Jessica Bauman, Gerson Peltz
Publikováno v:
Journal of Thoracic Oncology. 13:S322-S323
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55978e0ee2b055bb4c6e8625210fd6b7
https://doi.org/10.1016/j.jtho.2018.08.241
https://doi.org/10.1016/j.jtho.2018.08.241
Autor:
Revathi Ananthakrishnan, Birgit Geoerger, Jill S. Clancy, Sheri L. Spunt, Joseph Boni, Mizue Krygowski, Stephan A. Grupp, Anna Berkenblit, Danuta Perek, Mark W. Kieran
Publikováno v:
European Journal of Cancer. 48:253-262
A phase II study of temsirolimus was conducted in children and adolescents with high-grade glioma, neuroblastoma or rhabdomyosarcoma.Temsirolimus 75 mg/m(2) was administered once weekly until disease progression or intolerance. Using the Simon 2-stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756895d4f713b21dfd7addbf758b8f74
https://doi.org/10.1016/j.ejca.2011.09.021
https://doi.org/10.1016/j.ejca.2011.09.021
Autor:
S. Gadgeel, Todd M. Bauer, Ross A. Soo, S-H.I. Ou, Leonard P. James, Benjamin Besse, Takashi Seto, E. Felip Font, Antonello Abbattista, Jill S. Clancy, Ben Solomon, Alice T. Shaw
Publikováno v:
Annals of Oncology. 28:v478-v479
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8245319a60809844215c810416c5c44f
https://doi.org/10.1093/annonc/mdx380.045
https://doi.org/10.1093/annonc/mdx380.045